Vise Technologies Inc. acquired a new position in shares of Quest Diagnostics Incorporated (NYSE:DGX – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 3,611 shares of the medical research company’s stock, valued at approximately $765,000.
Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in shares of Quest Diagnostics by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 14,392,082 shares of the medical research company’s stock worth $2,497,458,000 after purchasing an additional 140,450 shares during the last quarter. BlackRock Inc. bought a new stake in Quest Diagnostics in the second quarter valued at about $1,965,923,000. State Street Corp raised its stake in Quest Diagnostics by 3.0% during the fourth quarter. State Street Corp now owns 5,382,547 shares of the medical research company’s stock valued at $934,033,000 after buying an additional 158,617 shares in the last quarter. Boston Partners raised its stake in Quest Diagnostics by 32.8% during the third quarter. Boston Partners now owns 4,036,881 shares of the medical research company’s stock valued at $767,978,000 after buying an additional 997,033 shares in the last quarter. Finally, Morgan Stanley lifted its holdings in Quest Diagnostics by 17.8% during the 4th quarter. Morgan Stanley now owns 2,693,568 shares of the medical research company’s stock worth $467,415,000 after buying an additional 406,658 shares during the last quarter. Institutional investors own 88.06% of the company’s stock.
Wall Street Analysts Forecast Growth
Several brokerages have recently commented on DGX. Robert W. Baird lifted their target price on Quest Diagnostics from $236.00 to $255.00 and gave the stock a “neutral” rating in a research report on Friday, July 24th. UBS Group upped their price target on Quest Diagnostics from $220.00 to $232.00 and gave the company a “neutral” rating in a research report on Friday, July 24th. Truist Financial raised their price objective on Quest Diagnostics from $225.00 to $250.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Barclays boosted their target price on shares of Quest Diagnostics from $230.00 to $250.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Finally, Jefferies Financial Group reissued a “buy” rating and set a $245.00 target price on shares of Quest Diagnostics in a report on Thursday, July 23rd. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat, Quest Diagnostics presently has an average rating of “Moderate Buy” and an average price target of $235.31.
Quest Diagnostics Trading Down 0.0%
Shares of NYSE DGX opened at $244.34 on Monday. The company has a market cap of $26.97 billion, a price-to-earnings ratio of 25.94, a price-to-earnings-growth ratio of 2.25 and a beta of 0.56. Quest Diagnostics Incorporated has a 12-month low of $171.18 and a 12-month high of $245.68. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.72. The stock’s 50 day simple moving average is $219.35 and its 200 day simple moving average is $205.29.
Quest Diagnostics (NYSE:DGX – Get Free Report) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $3.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.82 by $0.30. The business had revenue of $3.04 billion during the quarter, compared to analyst estimates of $2.97 billion. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%.The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.62 EPS. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. Equities research analysts expect that Quest Diagnostics Incorporated will post 11.15 EPS for the current year.
Quest Diagnostics Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 21st. Stockholders of record on Tuesday, October 6th will be given a dividend of $0.86 per share. The ex-dividend date is Tuesday, October 6th. This represents a $3.44 annualized dividend and a dividend yield of 1.4%. Quest Diagnostics’s payout ratio is currently 36.52%.
Insider Transactions at Quest Diagnostics
In other Quest Diagnostics news, SVP Mark E. Delaney sold 1,600 shares of Quest Diagnostics stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $235.18, for a total transaction of $376,288.00. Following the sale, the senior vice president owned 10,335 shares of the company’s stock, valued at $2,430,585.30. The trade was a 13.41% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karthik Kuppusamy sold 8,147 shares of Quest Diagnostics stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $200.00, for a total value of $1,629,400.00. Following the sale, the senior vice president directly owned 13,510 shares in the company, valued at $2,702,000. The trade was a 37.62% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 19,747 shares of company stock worth $3,947,088. Company insiders own 0.88% of the company’s stock.
About Quest Diagnostics
Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.
Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.
Read More
- Five stocks we like better than Quest Diagnostics
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGX – Free Report).
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
